IDO2 and neoplasm: Developed loading PD-1 signaling pathway peptide inhibitor (AUNP-12) and indoleamine-2,3-dioxygenase (IDO) inhibitor tumor cascade targeting the NLG919@Lip-pep1 system, after blood entry, AUNP-12 for the tumor cells high expression of PD-L1 significant targeting to achieve the delivery system in the tumor accumulation, and subsequently in the matrix metalloproteinase-2 (MMP-2) cleavage triggered the dissociation of AUNP-12, which restored T cell activity by precisely blocking the PD-1 signaling pathway.